How Investors Are Reacting To Madison Square Garden Sports (MSGS) Plant-Based Pivot And Spin-Off Talk

Madison Square Garden Co. Class A

Madison Square Garden Co. Class A

MSGS

0.00

  • In April 2026, Madison Square Garden Sports Corp. and Madison Square Garden Entertainment Corp. announced a multiyear partnership making Impossible Foods the Official Plant-Based Burger Partner of Madison Square Garden, the New York Knicks and the New York Rangers, including a new Impossible Grille concession and expanded plant-based offerings throughout the arena.
  • Alongside this operational update, renewed attention on the board’s exploration of a potential spin-off or minority stake sale has sharpened investor focus on the gap between Madison Square Garden Sports’ market value and the privately assessed worth of its core franchises.
  • Next, we’ll examine how the Impossible Foods partnership and heightened focus on a potential spin-off could reshape Madison Square Garden Sports’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Madison Square Garden Sports Investment Narrative Recap

To own Madison Square Garden Sports, you need to believe the enduring appeal of the Knicks and Rangers can support premium pricing, sponsorships, and media income despite recent earnings volatility and pressure on local media rights. The Impossible Foods partnership is incremental to that story rather than a major near term catalyst, while the board’s exploration of a spin off or minority stake sale remains the key potential re rating event and execution risk.

The multiyear Impossible Foods deal fits into a broader pattern of new partnerships, alongside recent agreements with Blueair and an extended Infosys relationship, that modestly deepen in arena monetization and brand reach. While these announcements do not directly address the structural reset in local media fees, they matter to the bullish view that sponsorship and in arena spending can partially offset media headwinds and support the value ascribed to the underlying franchises.

But against this backdrop, investors should also be aware that...

Madison Square Garden Sports' narrative projects $1.1 billion revenue and $107.0 million earnings by 2029. This requires fairly flat yearly revenue growth and a $123.6 million earnings increase from -$16.6 million today.

Uncover how Madison Square Garden Sports' forecasts yield a $348.60 fair value, a 5% upside to its current price.

Exploring Other Perspectives

MSGS 1-Year Stock Price Chart
MSGS 1-Year Stock Price Chart

While the baseline view treats partnerships like Impossible Grille as incremental, the most optimistic analysts saw room for US$1.1 billion of revenue and US$105.3 million of earnings by 2028, highlighting how sharply opinions can differ and why you may want to test these assumptions against your own expectations.

Explore 2 other fair value estimates on Madison Square Garden Sports - why the stock might be worth as much as 5% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Madison Square Garden Sports research is our analysis highlighting 3 important warning signs that could impact your investment decision.
  • Our free Madison Square Garden Sports research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madison Square Garden Sports' overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

  • This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
  • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
  • AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.